HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) appointed Professor Tan Shao Weng, Daniel as an Independent Non-executive Director and member of its Technical Committee effective 15 October 2025.
Professor Tan, age 47, brings >20 years in oncology, leads the NCCS Experimental Cancer Therapeutics Unit (running ~30–40 Phase I trials), and is principal investigator on an NMRC Lung Cancer grant (2025–2029). His annual director fees are US$76,000 plus US$8,000 for committee membership. The appointment term runs to the next AGM and then on successive 12‑month terms, subject to re‑election and company articles.
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) ha nominato il Professor Tan Shao Weng, Daniel come Consigliere indipendente non esecutivo e membro del suo Technical Committee con effetto dal 15 ottobre 2025.
Il Professor Tan, 47 anni, vanta oltre 20 anni di esperienza in oncologia, dirige l'Unità di Terapie Oncologiche Sperimentali del NCCS (in cui si svolgono circa 30–40 trial di fase I) ed è investigador principal su una sovvenzione NMRC sul cancro del polmone (2025–2029). Le sue spese annuali da direttore sono US$76,000 oltre a US$8,000 per l'appartenenza al comitato. Il mandato di nomina va fino alla prossima assemblea generale degli azionisti e poi per ulteriori mandati di 12 mesi, soggetti a ricandidatura e agli statuti della società.
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) nombró al Profesor Tan Shao Weng, Daniel como Director Independiente no ejecutivo y miembro de su Technical Committee con efecto a partir del 15 de octubre de 2025.
El Profesor Tan, de 47 años, aporta más de 20 años en oncología, dirige la Unidad de Terapias Oncológicas Experimentales del NCCS (realizando ~30–40 ensayos de Fase I) y es investigador principal de una subvención NMRC sobre cáncer de pulmón (2025–2029). Sus honorarios anuales como director son US$76,000, además de US$8,000 por membresía en el comité. El mandato de nombramiento se extiende hasta la próxima asamblea general y luego por mandatos sucesivos de 12 meses, sujeto a reelegición y a los estatutos de la empresa.
HUTCHMED (나스닥/ AIM: HCM, 홍콩증권거래소: 13)은 독립 비상무 이사로서 타니 샤오 웽 다니엘 교수와 기술위원회의 일원이 되도록 임명되었으며, 발효일은 2025년 10월 15일입니다.
타니 교수는 만 47세로 암학 분야에서 20년 넘는 경력을 가지고 있으며, NCCS 실험적 암 치료 단위를 이끌고(약 30~40건의 1상 임상시험 진행), NMRC 폐암 보조금(2025–2029)의 주임 연구자로 있습니다. 그의 이사 연간 수수료는 미화 76,000달러이고, 위원회 소속 수수료로 미화 8,000달러가 추가로 부여됩니다. 임명 기간은 다음 주주총회까지이며 이후 12개월 단위의 연임 조건부로 지속됩니다.
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) a nommé le Professeur Tan Shao Weng, Daniel en tant que Administrateur indépendant non exécutif et membre de son Comité technique à compter du 15 octobre 2025.
Le Professeur Tan, 47 ans, apporte plus de 20 ans d'expérience en oncologie, dirige l'Unité de thérapies expérimentales du cancer du NCCS (environ 30–40 essais de phase I en cours) et est le chercheur principal sur une subvention NMRC pour le cancer du poumon (2025–2029). Ses frais annuels de directeur s'élèvent à US$76 000 auxquels s'ajoutent US$8 000 pour l'appartenance au comité. Le mandat est valable jusqu'à la prochaine assemblée générale et se poursuit ensuite par des mandats successifs de 12 mois, sous réserve de réélection et des statuts de l'entreprise.
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) hat Professor Tan Shao Weng, Daniel zum Independent Non-executive Director und Mitglied seines Technical Committee mit Wirkung zum 15. Oktober 2025 ernannt.
Professor Tan, 47 Jahre alt, bringt mehr als 20 Jahre Erfahrung in der Onkologie mit, leitet die NCCS Experimental Cancer Therapeutics Unit (etwa 30–40 Phase-I-Studien) und ist Principal Investigator eines NMRC-Lungenkrebs-Zuschusses (2025–2029). Seine jährlichen Direktorenhonorare betragen US$76.000 plus US$8.000 für die Mitarbeit im Ausschuss. Die Ernennung gilt bis zur nächsten Hauptversammlung und anschließend in aufeinanderfolgenden 12-Monats-Verträgen, vorbehaltlich Wiederwahl und der Satzung des Unternehmens.
HUTCHMED (ناسداك/أيم: HCM، هونغ كونغ: 13) عيّنت الأستاذ تان شاو وينغ، دانيال كـ عضو فخري مستقل غير تنفيذي وعضو في لجنة التقنية اعتباراً من 15 أكتوبر 2025.
الأستاذ تان، البالغ من العمر 47 عاماً، يضفي أكثر من 20 عاماً من الخبرة في الأورام، يقود وحدة العلاجات التجريبية للأورام في NCCS (تشغيل نحو 30–40 تجربة من المرحلة الأولى)، وهو الباحث الرئيسي في منحة NMRC لسرطان الرئة (2025–2029). رسومه السنوية كمدير هي 76,000 دولار أمريكي إضافة إلى 8,000 دولار مقابل عضويته في اللجنة. تستمر فترة التعيين حتى AGM القادمة ثم في فترات 12 شهرية متعاقبة، رهناً بإعادة انتخابه وبمواد الشركة.
HUTCHMED (纳斯达克/ AIM: HCM，香港交易所: 13) 任命 Tan Shao Weng, Daniel 教授为 独立非执行董事 并成为其技术委员会成员，生效日期为 2025年10月15日。
Tan 教授，47岁，在肿瘤学领域具有超过20年的经验，领导 NCCS 实验性癌症治疗单位（约运行30–40项I期试验），并担任 NMRC 肺癌资助的首席研究员（2025–2029）。他担任董事的年薪为 US$76,000，另有 US$8,000 的委员会成员费。任期直到下次股东大会，随后按12个月连续任期继续，须经连任及公司章程之规定。
- Adds oncology drug‑development expertise with 20+ years experience
- Leads a Phase I unit running ~30–40 concurrent trials
- Named PI on NMRC Lung Cancer grant for 2025–2029
- Initial appointment only until next AGM, requiring re‑election
- Director fees set at US$76,000 plus US$8,000 may signal modest cost
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025.
Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the National Cancer Centre Singapore (“NCCS”). He is a professor at Duke-NUS Medical School and serves as a senior clinician-scientist at the Genome Institute of Singapore.
Dr Dan Eldar, Chairman of HUTCHMED, said “On behalf of the Board, I would like to extend a warm welcome to Professor Tan. Professor Tan has a proven track record in early phase clinical trials of novel therapeutics, and we believe that his expertise in targeted therapies, biomarker development and clinical oncology will strongly support the strategic growth of the Company and drive continued innovation in cancer drug development.”
Professor Tan currently leads the Experimental Cancer Therapeutics Unit (ECRU) at the NCCS, one of Asia’s largest Phase I units, which runs approximately 30–40 trials at any time. He is also the Principal Investigator of the Cancer Therapeutics Research Laboratory at NCCS focused on developing representative patient-derived preclinical models to study drug response and resistance, complementing his leadership in multiple biomarker-driven early-phase and first-in-human clinical trials. He currently serves as the principal investigator of the National Medical Research Council (“NMRC”) Lung Cancer Large Collaborative Grant in Singapore (2025-2029 and previously 2019–2023) and chairs the Asian Thoracic Oncology Research Group, a regional platform for translational research and clinical trials.
Professor Tan’s research focuses on applying “omics” technologies to understand drug resistance and accelerate the development of novel therapies and biomarkers. His work has earned numerous accolades, including the International Association for the Study of Lung Cancer (IASLC) Daniel C. Idhe Lectureship Award for Medical Oncology, the American Society of Clinical Oncology (ASCO) Young Investigator Award, and the SingHealth Group Chief Executive Officer Outstanding Clinician-Researcher Award. He is a three-time recipient of the NMRC Clinician-Scientist Award.
He has published extensively, contributing to over 200 peer-reviewed articles including those in leading journals such as Nature, Nature Medicine, New England Journal of Medicine, and The Lancet Oncology. Professor Tan has held leadership roles in global oncology forums, including Chair of the IASLC Education Committee and Co-Chair of the World Conference on Lung Cancer (WCLC). He currently serves as Associate Editor for the Journal of Thoracic Oncology, Scientific Editor for Cancer Discovery and Senior Editor for Clinical Cancer Research. He is a member of the American Association of Cancer Research (AACR), ASCO, the European Society for Medical Oncology (ESMO), IASLC and the Singapore Society of Oncology of which he was also a past secretary.
Professor Tan holds a Bachelor of Science degree with first class honors in tumor biology from University College London, University of London; a Bachelor of Medicine and Bachelor of Surgery from St Bartholomew’s and the Royal London School of Medicine and Dentistry; and a PhD from the National University of Singapore. He is a member of the Royal College of Physicians of the United Kingdom.
Additional Disclosure Pursuant to the AІM Rules for Companies and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“HK Listing Rules”)
Professor Tan is currently a director of Epoch Biosciences Pte. Ltd. Save for this appointment, Professor Tan has held no other directorships or partnerships during the period of five years prior to his appointment as a director of HUTCHMED. He does not have any relationship with any Directors, senior management or substantial or controlling shareholders of HUTCHMED. Professor Tan has confirmed (a) his independence as regards each of the factors for independence referred to in Rule 3.13(1) to (8) of the HK Listing Rules; (b) that he had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the HK Listing Rules) of the Company; and (c) that there are no other factors that may affect his independence at the time of his appointment.
The initial term of the appointment of Professor Tan as an Independent Non-executive Director of the Company shall end at the next following annual general meeting of the Company, subject to retirement in accordance with the Articles of Association of the Company and applicable legal and regulatory requirements, and thereafter for successive periods of 12 months, unless he is not re-elected at the next following annual general meeting or his appointment is otherwise terminated earlier by either party in writing. The director’s fees of Professor Tan as an Independent Non-executive Director and member of the Technical Committee of the Company under his appointment letter are US
Professor Tan does not have any interest in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).
Save for the information disclosed above, there is no other information in relation to Professor Tan that is required to be disclosed pursuant to Rule 17 and Schedule 2(g) of the AІM Rules for Companies or Rule 13.51(2) of the HK Listing Rules, and there are no other matters concerning the appointment of Professor Tan that are required to be brought to the attention of the shareholders of HUTCHMED.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the risk that current or future appointees to HUTCHMED’s board of directors are not effective in their respective positions, the difficulty in locating and recruiting suitable candidates for its board of directors and the management difficulties which may arise from changes in HUTCHMED’s board of directors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, on AІM and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
FAQ
When does HUTCHMED (HCM) appoint Professor Tan as director?
What role will Professor Tan hold at HUTCHMED (HCM)?
How much will HUTCHMED (HCM) pay Professor Tan annually?
What clinical experience does Professor Tan bring to HUTCHMED (HCM)?
How long is Professor Tan's initial term as HUTCHMED (HCM) director?
